Researchers conducted a meta-analysis to assess the efficacy and safety of Tacrolimus (TAC) in induction therapy of people with lupus nephritis (LN). TAC is an immunosuppressant used in kidney transplantation. They concluded that TAC is an effective and safe agent for LN therapy and encourage more study to confirm their findings. TAC is often used in LN as an alternative to standard therapies. LN is one of the most serious complications of SLE and occurs in up to 60% of patients worldwide; among them, 50%–80% are pediatric-onset SLE cases. Without drug intervention, long-term inflammation may cause irreversible damage to kidney and may cause chronic kidney disease, which subsequently develops into end-stage renal disease. Learn about lupus in the kidney.
There are multiple chapters near you. Select your preferred chapter.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving southern Illinois up to and including Springfield, eastern Kansas, and Missouri
Serving northern and central Illinois
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas
Serving all northern counties in New Jersey, south through Mercer and Ocean counties
Supporting lupus patients and advocates in New York and Connecticut.
Serving Philadelphia and southeastern Pennsylvania, all southern counties in New Jersey up through Burlington county, and Delaware
Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas
There are multiple walks near you.